Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

I had been taking Zepbound for about six months when it clicked. My period — the monster that turned me from a functioning ...

Injection site reactions, such as bleeding or pain, were common side effects of Zepbound. These reactions should go away on their own within a few days of injecting your Zepbound dose. But ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...

Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...

Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...

This loss must be maintained to continue seeing the effects of the medicine. Lifestyle recommendations that may help alongside the use of Zepbound include: Overeating has been associated with poor ...